• Enisamium iodide use experience in the clinic of acute respiratory diseases: a literature review

Enisamium iodide use experience in the clinic of acute respiratory diseases: a literature review

SOVREMENNAYA PEDIATRIYA.2018.5(93):65-70; doi 10.15574/SP.2018.93.65

Marushko Yu. V., Hyshchak T. V.
Bogomolets National Medical University, Kyiv, Ukraine

The acute respiratory diseases (ARI) morbidity of children is on top of its relevancy. The regulations governing the patient with influenza and acute respiratory disease management emphasize the need for rational organization of therapy, a differentiated approach to antibiotics administration, in order to avoid polypragmasy. Administration of drugs that able of comprehensively affecting both the aetiological factors of ARI and the pathogenetic mechanisms of their development allows solving these problems. Enisamium iodide is such a drug. Clinically proven Enisamium iodide high efficacy, due to its antiviral, immunomodulatory and anti-inflammatory effects, allows to recommend Enisamium iodide-based preparations for the broad-spectrum application in influenza and acute respiratory disease therapy.
Key words: acute respiratory diseases, treatment, Enisamium iodide.

REFERENCES

1. Amizon proty hrypu ta HRVI: rezultaty mizhnarodnoho doslidzhennia. (2014). Zdorovia Ukrainy. 21: 24—25.

2. Zhulai TS, Shebeko SK, Zupanets IA. (2017). Doslidzhennia dozozalezhnosti antyeksudatyvnoi dii novoho nazalnoho spreiu z protyzapalnymy vlastyvostiamy. Klinichna farmatsiia. 21; 4: 11—16.

3. Isakov VA, Ohapkina EA, Evgrafov VD. (2015). Effektivnost Amizona v terapiii profilaktike grippa i ORVI. Meditsinskiy forum. 1 (2): 3—6.

4. Marushko YuV, Melnykov OF, Hrachova MH, Movchan OS. (2013). Efektyvnist zastosuvannia preparatu «Amizonchyk» pry hostrykh respiratornykh zakhvoriuvanniakh u ditei vikom 3—6 rokiv. Sovremennaia pedyatryia. 4(52): 62—66.

5. Marushko YuV, Sabadash EE. (2015). Kliniko-eksperymentalna kharakterystyka amizonu y dosvid zastosuvannia v klinichnii praktytsi Zdorove rebenka. 6 (67): 26—31.

6. Marushko YuV. (2017, ver.). Vyvchennia protyvirusnykh, protyzapalnykh ta zharoznyzhuvalnykh vlastyvostei enisamiumu yodydu. Zdorovia Ukrainy. Pediatriia. 3 (42): 51.

7. Melnikova TI, Deeva EG, Amosova IV i dr. (2013, ver.). Klinicheskaya effektivnost Amizona v terapii grippa i drugih ostryih respiratornyih virusnyih infektsiy. Zdorovia Ukrainy. 17 (318): 40—41.

8. Melnikova TI, Deeva EG, Ohapkina EA. i dr. (2012). Klinicheskaya effektivnost preparata na osnove izonikotinovoy kislotyi v terapii grippa i drugih ostryih respiratornyih virusnyih zabolevaniy. Infektsionnyie bolezni. 4: 70—75.

9. Olhovskaya ON, Kuznetsov SV, Zharkova TS. (2014). Effektivnost primeneniya preparata Amizonchik v kompleksnoy terapii detey, bolnyih ostryimi respiratornyimi virusnyimi infektsiyami. Pediatriya. Vostochnaya Evropa. 1: 92—99.

10. Pro zatverdzhennia i vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry hrypi i hostrykh respiratornykh infektsiiakh: nakaz MOZ Ukrainy vid 16.07.2014 No. 499. http://www.moz.gov.ua.

11. Prospektivnoe prostoe slepoe sravnitelnoe klinicheskoe issledovanie po izucheniyu effektivnosti i bezopasnosti preparata «Amizon» tabletok 0,25 g, proizvodstva kompanii OAO «Farmak» u patsientov s ORVI, v tom chisle grippom. http://www.influenza.spb.ru/science_work/clinical_tests/amizon_3_phase. Accessed November 17, 2014.

12. Frolov AF, Frolov VM, Loskutova IV. (2000). Amizon: opyit primeneniya v pediatricheskoy praktike. Ukrainskyi medychnyi chasopys. 2(16): 97—100.

13. Frolov AF, Frolov VM. (2005). Effektivnost Amizona v lechenii i profilaktike virusnyih infektsiy (k 10-letiyu primeneniya preparata v klinicheskoy praktike). Ukrainskyi medychnyi chasopys. 5(49): 75—80.

14. 3-rd anivirals congress. http://www.antivirals.elsevier.com/conference-programme.html.

15. Boltz D, Cocking D, Cinatl J et al. (2017). Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Programme and Abstract Book, 5th ISIRV AVG Conference, Shanghai, China: 110.

16. Boltz D, Peng X, Muzzio M еt al. (2014). Antiviral Activity of Enisamium Against Influenza Viruses in Differentiated Normal Human Bronchial Epithelial Cells. 3rd Antivirals Congress (October 12—14, 2014). Amsterdam, Netherlands.

17. Chi Y, Zhu Y, Wen T et al. (2013). Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China. J Infect Dis. 208: 1962—1967.

18. Cocking D, Cinatl J, Boltz DA, Peng X, Johnson W et al. (2018). Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol. 62(2): 191—195.

19. Farzin H, Toroghi R, Haghparast A. (2016). Up-Regulation of Pro-Inflammatory Cytokines and Chemokine Production in Avian Influenza H9N2 Virus-Infected Human Lung Epithelial Cell Line (A549). Immunol Invest. 45: 116—129.

20. Hagau N, Slavcovici A, Gonganau DN et al. (2010). Clinical aspects and cytokine response in severe H1N1 influenza A virus infection. Crit Care. 14. P.R203. https://doi.org/10.1186/cc9324; PMid:21062445 PMCid:PMC3220006

21. Haltner-Ukоmadu E, Gureyеva S, Burmakа O et al. (2018). In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide. Sci Phаrm. 11; 86(1). https://doi.org/10.3390/scipharm86010003; PMid:29324660 PMCid:PMC5874533

22. Jingxian Chen RZ, Tao Peng, Dapeng Xiang, Mingli Wang (2012). Clinical Virology. China Science Publishing & Media Ltd: 950—983.

23. Lee N, Wong CK, Chan PK et al. (2011). Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One. 6: 26050.

24. Li Z, Li L, Zhao S et al. (2018). Re-undеrstаnding anti-influenzа strategy: attаch еqual importance to antiviral аnd anti-inflammatory th erapies. Thorac Dis. 10 (19): 2248—2259.

25. Michaelis M. Doerr HW, Cinatl J et al. (2009). An influenza A H1N1 virus revival — pandemic H1N1/09 virus. Infection. 37: 381—389.

26. Peiris JS, Hui KP, Yen HL. (2010). Host response to influenza virus: protection versus immunopathology. Curr Opin Immunol. 22: 475—481.

27. Tisoncik JR, Korth MJ, Simmons CP et al. (2012). Into the eye of the cytokine storm. Microbiol Mol Biol Rev 76: 16—32.

28. Vaccines against influenza WHO position paper. (2012, Nov.). Wkly Epidemiol Rec. 87: 461—476.

29. World Health Organization. Influenza. http://www.who.int/ru/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year

30. Yang ZF, Mok CK, Liu XQ et al. (2015). Clinical, virological and immunological features from patients infected with re-emergent avian-origin human H7N9 influenza disease of varying severity in Guangdong province. PloS one. 10: 0117846.

31. Yip TF, Selim ASM, Lian I, Lee SM. (2018). Advancements in Host-Based Interventiоns for Influenza Treatment. Front Immunol. 10 (9): 1547.

32. Zhou J, Wang D, Gao R et al. (2013). Biological features of novel avian influenza A (H7N9) virus. Nature. 499: 500—503.

Article received: Mar 12, 2018. Accepted for publication: Jul 20, 2018.